impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

The effect of anti-TNF treatment on osteoblastogenesis in ankylosing spondylitis: the number of circulating osteoblast-lineage cells in peripheral blood decreased after infliximab therapy in patients with ankylosing spondylitis

1, 2, 3, 4, 5, 6, 7

 

  1. Rheumatism Centre, Department of Internal Medicine, School of Medicine, Inha University, Incheon, Republic of Korea.
  2. Rheumatism Centre, Department of Internal Medicine, School of Medicine, Inha University, Incheon, Republic of Korea.
  3. Rheumatism Centre, Department of Internal Medicine, School of Medicine, Inha University, Incheon, Republic of Korea.
  4. Rheumatism Centre, Department of Internal Medicine, School of Medicine, Inha University, Incheon, Republic of Korea.
  5. Biomedical and Biological Sciences, School of Medicine, Inha University, Inha University, Incheon, Republic of Korea.
  6. Occupational and Environmental Medicine, School of Medicine, Inha University, Incheon, Republic of Korea.
  7. Rheumatism Centre, Department of Internal Medicine, School of Medicine, Inha University, Incheon, Republic of Korea. parkwon@inha.ac.kr

CER10073
2017 Vol.35, N°5
PI 0837, PF 0843
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 28375831 [PubMed]

Received: 06/11/2016
Accepted : 14/02/2017
In Press: 31/03/2017
Published: 15/09/2017

Abstract

OBJECTIVES:
The full effect of anti-TNF therapy on new bone formation is still in debate in spondylitis fields. We sought to obtain circulating osteoblast-lineage cells in peripheral blood from ankylosing spondylitis (AS) patients and healthy control subjects, and to evaluate the effect of before and after anti TNF-α therapy on osteoblastogenesis in patients with AS.
METHODS:
Sixteen male patients with AS slated for infliximab therapy and 19 controls were recruited. We cultured osteoblast-lineage cells from peripheral blood and measured the optical density of their Alizarin red S staining. We also measured serum P1NP (procollagen type 1 N-terminal propeptide) as an early osteoblast differentiation marker, osteocalcin as a late osteoblast differentiation marker, and inflammatory markers.
RESULTS:
There were significantly more circulating osteoblast-lineage cells in patients than in controls. The number of circulating osteoblast-lineage cells and optical density of Alizarin red S staining decreased 14 weeks after infliximab therapy (p=0.028); serum level of P1NP decreased, but that of osteocalcin increased (p=0.002 and 0.007, respectively).
CONCLUSIONS:
Our data reveals that first, the circulating osteoblast-lineage cells are recoverable and increased in AS patients, and also that they decrease after infliximab therapy; second, infliximab therapy resolves early inflammation, but allows mature osteoblast differentiation in late inflammation. The culture of osteoblast-lineage cells in peripheral blood may be a candidate for a new modality with which to study spondylitis and other autoimmune diseases.

Rheumatology Article